



## Pre-Transplant Essential Data: Disease Classification

### CIBMTR Use Only

Sequence Number:

Date Received:

~~(Request for OMB approval will be submitted when form is complete)~~

### OMB Placeholder

OMB No: ~~0915-0310~~

Expiration Date:

**Public Burden Statement:** An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0915-0310.

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

Event date: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

HCT type: *(check all that apply)*

- ☐ Autologous
- ☐ Allogeneic, unrelated
- ☐ Allogeneic, related

Product type: *(check all that apply)*

- ☐ Bone marrow
- ☐ PBSC
- ☐ Single cord blood unit
- ☐ Multiple cord blood units
- ☐ Other product

Specify: \_\_\_\_\_

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

### Primary Disease for HCT

1. Date of diagnosis of primary disease for HCT: \_\_\_\_\_  
YYYY MM DD

2. What was the primary disease for which the HCT was performed?

- ☐ Acute myelogenous leukemia (AML or ANLL) (10) - **Go to question 3**
- ☐ Acute lymphoblastic leukemia (ALL) (20) - **Go to question 64**
- ☐ ~~Other~~ **Acute leukemia of ambiguous lineage and other myeloid neoplasms** (80) - **Go to question 107**
- ☐ Chronic myelogenous leukemia (CML) (40) - **Go to question 1121**
- ☐ Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease) - **Go to question 1235**
- ☐ Other leukemia (30) (includes CLL) - **Go to question 2178**
- ☐ Hodgkin lymphoma (150) - **Go to question 2245**
- ☐ Non-Hodgkin lymphoma (100) - **Go to question 2278**
- ☐ Multiple myeloma / plasma cell disorder (PCD) (170) - **Go to question 2334**
- ☐ Solid tumors (200) - **Go to question 2656**
- ☐ Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease) - **Go to question 2678**
- ☐ Inherited abnormalities of erythrocyte differentiation or function (310) - **Go to question 26970**
- ☐ Disorders of the immune system (400) - **Go to question 2723**
- ☐ Inherited abnormalities of platelets (500) - **Go to question 2756**
- ☐ Inherited disorders of metabolism (520) - **Go to question 2778**
- ☐ Histiocytic disorders (570) - **Go to question 27980**
- ☐ Autoimmune diseases (600) - **Go to question 2812**
- ☐ Other disease (900) - **Go to question 28990**

### Acute Myelogenous Leukemia (AML)

3. Specify the AML classification:

#### **AML with recurrent genetic abnormalities**

- ☐ AML with t(9;11) (p22.3;q23.3); MLLT3-KMT2A~~MLL~~ (5)
- ☐ AML with t(6;9) (p23;q34.1); DEK-NUP214 (6)
- ☐ AML with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); ~~RPN1-EVI1~~GATA2, MECOM (7)

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

- ☐ AML (megakaryoblastic) with t(1;22) (p13.3;q13.3); RBM15-MKL1 (8)
- ☐ AML with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 (281)
- ☐ AML with inv(16)(p13.1;q22) or t(16;16)(p13.1; q22); CBFβ-MYH11 (282)
- ☐ APL with t(15;17)(q22;q12); PML-RARA (283)

☐ ☐ AML with BCR-ABL1 (provisional entity)

☐ ☐ AML with mutated NPM1

☐ ☐ AML with biallelic mutations of CEBPA

☐ ☐ AML with mutated RUNX1 (provisional entity)

- ☐ AML with 11q23 (MLL) abnormalities (i.e., t(4;11), t(6;11), t(9;11), t(11;19)) (284)
- ☐ AML with myelodysplasia – related changes (285)
- ☐ Therapy related ~~AML (t-AML) (9)~~ AML (t-AML) (9)

#### AML, not otherwise specified

☐ ~~Myeloid sarcoma (295)~~

☐ ~~Blastic plasmacytoid dendritic cell neoplasm (296)~~

- ☐ AML ~~or ANLL~~, not otherwise specified (280)
- ☐ AML, minimally differentiated ~~(M0)~~ (286)
- ☐ AML without maturation ~~(M1)~~ (287)
- ☐ AML with maturation ~~(M2)~~ (288)
- ☐ Acute myelomonocytic leukemia ~~(M4)~~ (289)
- ☐ Acute monoblastic / acute monocytic leukemia ~~(M5)~~ (290)
- ☐ Acute erythroid leukemia (erythroid / myeloid and pure erythroleukemia) ~~(M6)~~ (291)
- ☐ Acute megakaryoblastic leukemia ~~(M7)~~ (292)
- ☐ Acute basophilic leukemia (293)
- ☐ Acute panmyelosis with myelofibrosis (294)
- ☐ Myeloid sarcoma (295)
- ☐ ☐ Myeloid leukemia associated with Down syndrome

4. \_\_\_\_\_ Did AML transform from MDS or MPN?

- ☐ Yes – **Also complete MDS Disease Classification questions**
- ☐ No

5. \_\_\_\_\_ Is the disease (AML) therapy related?

- ☐ Yes
- ☐ No
- ☐ Unknown

6. Did the recipient have a predisposing condition?

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

- ☐ Yes - **Go to question 7**
- ☐ No - **Go to question 9**
- ☐ Unknown - **Go to question 9**

7. Specify condition:

- ☐ Bloom syndrome - **Go to question 9**
- ☐ Down syndrome - **Go to question 9**
- ☐ Fanconi anemia - **Go to question 9**
- ☐ Neurofibromatosis type 1 - **Go to question 9**
- ☐ Other condition - **Go to question 8**

8. Specify other condition: \_\_\_\_\_

9. Were cytogenetics tested (karyotyping or FISH)?

☐ Yes - **Go to question 10**

☐ No - **Go to question 47**

☐ Unknown - **Go to question 47**

10. Results of tests:

☐ Abnormalities identified – **Go to question 11**

☐ No evaluable metaphases - **Go to question 47**

☐ No abnormalities - **Go to question 47**

**Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:**

**Monosomy**

11. -5

☐ Yes

☐ No

12. -7

☐ Yes

☐ No

13. -17

☐ Yes

☐ No

14. -18

☐ Yes

☐ No

15. -X

☐ Yes

☐ No

16. -Y

☐ Yes

☐ No

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

### Trisomy

17. +4

☐ Yes

☐ No

18. +8

☐ Yes

☐ No

19. +11

☐ Yes

☐ No

20. +13

☐ Yes

☐ No

21. +14

☐ Yes

☐ No

22. +21

☐ Yes

☐ No

23. +22

☐ Yes

☐ No

### Translocation

24. t(3;3)

☐ Yes

☐ No

25. t(6;9)

☐ Yes

☐ No

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

26. t(8;21)

☐ Yes

☐ No

27. t(9;11)

☐ Yes

☐ No

28. t(9;22)

☐ Yes

☐ No

29. t(15;17) and variants

☐ Yes

☐ No

30. t(16;16)

☐ Yes

☐ No

**Deletion**

31. del(3q) / 3q-

☐ Yes

☐ No

32. del(5q) / 5q-

☐ Yes

☐ No

33. del(7q) / 7q-

☐ Yes

☐ No

34. del(9q) / 9q-

☐ Yes

☐ No

35. del(11q) / 11q-

☐ Yes

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ ☐ No

36. del(16q) / 16q-

☐ ☐ Yes

☐ ☐ No

37. del(17q) / 17q-

☐ ☐ Yes

☐ ☐ No

38. del(20q) / 20q-

☐ ☐ Yes

☐ ☐ No

39. del(21q) / 21q-

☐ ☐ Yes

☐ ☐ No

#### **Inversion**

40. inv(3)

☐ ☐ Yes

☐ ☐ No

41. inv(16)

☐ ☐ Yes

☐ ☐ No

#### **Other**

42. (11q23) any abnormality

☐ ☐ Yes

☐ ☐ No

43. 12p any abnormality

☐ ☐ Yes

☐ ☐ No

44. Complex -  $\geq 3$  distinct abnormalities

☐ ☐ Yes



CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ ☐ No

45. Other abnormality

☐ ☐ Yes - **Go to question 46**

☐ ☐ No - **Go to question 47**

46. Specify other abnormality: \_\_\_\_\_

47. Were tests for molecular markers performed (e.g. PCR)?

☐ Yes – **Go to question 48**

☐ No – **Go to question 57**

☐ Unknown – **Go to question 57**

**Specify molecular markers identified at any time prior to the start of the preparative regimen:**

48. CEBPA

☐ Positive

☐ Negative

☐ Not done

49. FLT3 – D835 point mutation

☐ Positive

☐ Negative

☐ Not done

50. FLT3 – ITD mutation

☐ Positive

☐ Negative

☐ Not done

51. IDH1

☐ Positive

☐ Negative

☐ Not done

52. IDH2

☐ Positive

☐ Negative

☐ Not done

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

53. KIT

- ☐ Positive  
☐ Negative  
☐ Not done

54. NPM1

- ☐ Positive  
☐ Negative  
☐ Not done

55. Other molecular marker

- ☐ Positive- **Go to question 56**  
☐ Negative- **Go to question 56**  
☐ Not done- **Go to question 57**

56. Specify other molecular marker: \_\_\_\_\_

#### Status at transplantation

57. \_\_\_\_\_ What was the disease status (based on hematologic test results)?

- ☐ Primary induction failure – **Go to question 63**  
☐ 1st complete remission (no previous bone marrow or extramedullary relapse) – **Go to question 58**  
☐ 2nd complete remission – **Go to question 58**  
☐ ≥ 3rd complete remission – **Go to question 58**  
☐ 1st relapse – **Go to question 62**  
☐ 2nd relapse – **Go to question 62**  
☐ ≥ 3rd relapse – **Go to question 62**  
☐ No treatment – **Go to question 63**

58. How many cycles of induction therapy were required to achieve CR?

- ☐ 1  
☐ 2  
☐ ≥ 3

59. Was the recipient in molecular remission?

- ☐ Yes  
☐ No  
☐ Unknown  
☐ Not applicable

60. Was the recipient in remission by flow cytometry?

☐ Yes

☐ No

☐ Unknown

☐ Not applicable

61. Was the recipient in cytogenetic remission?

☐ Yes – **Go to question 63**

☐ No – **Go to question 63**

☐ Unknown – **Go to question 63**

☐ Not applicable– **Go to question 63**

62. Date of most recent relapse: \_\_\_\_\_

YYYY

MM

DD

63. Date assessed: \_\_\_\_\_ - **Go to signature line**

YYYY

MM

DD

### Acute Lymphoblastic Leukemia (ALL)

64. \_\_\_\_\_ Specify ALL classification:

#### **B-lymphoblastic leukemia / lymphoma**

☐ **B-lymphoblastic leukemia/lymphoma with** t(9;22)(q34.1;q11.2); BCR-ABL1 (192)

☐ **B-lymphoblastic leukemia/lymphoma with** t(v;11q23.3); MLL-rearrangedKMT2A rearranged (193)

☐ **B-lymphoblastic leukemia/lymphoma with** t(1;19)(q23;p13.3); E2A-PBX1TCF3-PBX1 (194)

☐ **B-lymphoblastic leukemia/lymphoma with** t(12;21) (p13.2;q22.1); TEL-AML1ETV6-RUNX1 (195)

☐ **B-lymphoblastic leukemia/lymphoma with** t(5;14) (q31.1;q32.3); IL3-IGH (81)

☐ **B-lymphoblastic leukemia/lymphoma with** Hyperdiploidy (51-65 chromosomes) (82)

☐ **B-lymphoblastic leukemia/lymphoma with** Hypodiploidy (<45 chromosomes) (83)

☐ **B-lymphoblastic leukemia/lymphoma with** (B-cell ALL, NOS)-{L1/L2} (191)

☐ **B-lymphoblastic leukemia/lymphoma, BCR-ABL1-like (provisional entity)**

☐ **B-lymphoblastic leukemia/lymphoma, with iAMP21 (provisional entity)**

☐ **T-cell lymphoblastic leukemia / lymphoma**-(Precursor T-cell ALL)-(196)

☐ **Early T-cell precursor lymphoblastic leukemia (provisional entity) (#)**

☐ ☐ Natural killer (NK)- cell lymphoblastic leukemia/lymphoma (provisional entity) (#) ☐ \_\_\_\_\_ ALL, NOS (199)

65. Were tyrosine kinase inhibitors (i.e. imatinib mesylate) given for pre-HCT therapy at any time prior to start of the preparative regimen?

☐ Yes

☐ No

66. Were cytogenetics tested (karyotyping or FISH)?

☐ Yes - **Go to question 67**

☐ No - **Go to question 95**

☐ Unknown - **Go to question 95**

67. Results of tests:

☐ Abnormalities identified – **Go to question 68**

☐ No evaluable metaphases - **Go to question 95**

☐ No abnormalities - **Go to question 95**

**Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen.**

#### **Monosomy**

68. -7

☐ Yes

☐ No

#### **Trisomy**

69. +4

☐ Yes

☐ No

70. +8

☐ Yes

☐ No

71. +17

☐ Yes

☐ No

72. +21

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ Yes

☐ No

### Translocation

73. t(1;19)

☐ Yes

☐ No

74. t(2;8)

☐ Yes

☐ No

75. t(4;11)

☐ Yes

☐ No

76. t(5;14)

☐ Yes

☐ No

77. t(8;14)

☐ Yes

☐ No

78. t(8;22)

☐ Yes

☐ No

79. t(9;22)

☐ Yes

☐ No

80. t(10;14)

☐ Yes

☐ No

81. t(11;14)

☐ Yes

☐ No

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

82. t(12;21)

☐ Yes

☐ No

#### Deletion

83. del(6q) / 6q–

☐ Yes

☐ No

84. del(9p) / 9p–

☐ Yes

☐ No

85. del(12p) / 12p–

☐ Yes

☐ No

#### Addition

86. add(14q)

☐ Yes

☐ No

#### Other

87. (11q23) any abnormality

☐ Yes

☐ No

88. 9p any abnormality

☐ Yes

☐ No

89. 12p any abnormality

☐ Yes

☐ No

90. Hyperdiploid (> 50)

☐ Yes

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ No

91. Hypodiploid (< 46)

☐ Yes

☐ No

92. Complex - ≥3 distinct abnormalities

☐ Yes

☐ No

93. Other abnormality

☐ Yes - **Go to question 94**

☐ No - **Go to question 95**

94. Specify other abnormality: \_\_\_\_\_

95. Were tests for molecular markers performed (e.g. PCR)?

☐ Yes – **Go to question 96**

☐ No – **Go to question 100**

☐ Unknown – **Go to question 100**

**Specify molecular markers identified at any time prior to the start of the preparative regimen:**

96. BCR / ABL

☐ Positive

☐ Negative

☐ Not done

97. TEL-AML / AML1

☐ Positive

☐ Negative

☐ Not done

98. Other molecular marker

☐ Positive – **Go to question 99**

☐ Negative – **Go to question 99**

☐ Not done – **Go to question 100**

99. Specify other molecular marker: \_\_\_\_\_

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

**Status at Transplantation:**

100. \_\_\_\_\_ What was the disease status (based on hematologic test results)?

☐ Primary induction failure – **Go to question 106**

☐ 1st complete remission (no previous marrow or extramedullary relapse) – **Go to question 101**

☐ 2nd complete remission – **Go to question 101**

☐ ≥ 3rd complete remission – **Go to question 101**

☐ 1st relapse – **Go to question 105**

☐ 2nd relapse – **Go to question 105**

☐ ≥ 3rd relapse – **Go to question 105**

☐ No treatment – **Go to question 106**

101. How many cycles of induction therapy were required to achieve CR?

☐ 1

☐ 2

☐ ≥ 3

102. Was the recipient in molecular remission?

☐ Yes

☐ No

☐ Unknown

☐ Not applicable

103. Was the recipient in remission by flow cytometry?

☐ Yes

☐ No

☐ Unknown

☐ Not applicable

104. Was the recipient in cytogenetic remission?

☐ Yes – **Go to question 461106**

☐ No – **Go to question 461106**

☐ Unknown – **Go to question 461106**

☐ Not applicable – **Go to question 461106**

105. Date of most recent relapse: \_\_\_\_\_  
YYY YYY DD

106. Date assessed: \_\_\_\_\_ - **Go to signature line**



CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

YYYY

MM

DD

### Other Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms

107. \_\_\_\_\_ Specify other acute leukemias of ambiguous lineage and other myeloid neoplasm classification:

☐ Acute leukemia of ambiguous lineage - Go to question 108

☐ Blastic plasmacytoid dendritic cell neoplasm – Go to question 110

108. \_\_\_\_\_ Specify acute leukemias of ambiguous lineage classification:

☐ Acute undifferentiated leukemia (31) ~~Go to question 109~~

☐ Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1

☐ Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged

☐ Mixed phenotype acute leukemia, B/myeloid, NOS

☐ Mixed phenotype acute leukemia, T/myeloid, NOS

☐ Biphenotypic, bilineage or hybrid leukemia (32) – Go to question 109

☐ Acute mast cell leukemia (33) – Go to question 109

☐ Other acute leukemia of ambiguous lineage (8#19) - Go to question 1098

109. \_\_\_\_\_ Specify other acute leukemia: \_\_\_\_\_

### Status at Transplantation:

110. \_\_\_\_\_ What was the disease status (based on hematologic test results)?

☐ Primary induction failure

☐ 1st complete remission (no previous marrow or extramedullary relapse)

☐ 2nd complete remission

☐ ≥ 3rd complete remission

☐ 1st relapse

☐ 2nd relapse

☐ ≥3rd relapse

☐ No treatment

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

111. Date assessed: \_\_\_\_\_ - **Go to signature line**

YYYY

MM

DD

### Chronic Myelogenous Leukemia (CML)

**Philadelphia chromosome+, Ph+, t(9;22)(q34;q11), or variant OR bcr/abl+**

**112. Specify CML classification:**

☐ **Ph+ / bcr+ (41)**

☐ **Ph+ / bcr- (42)**

☐ **Ph+ / bcr unknown (43)**

☐ **Ph- / bcr+ (44)**

☐ **Ph unknown / bcr+ (47)**

**113. Was therapy given prior to this HCT?**

☐ **Yes - Go to questions 1133**

☐ **No - Go to question 1199**

**114. Combination chemotherapy**

☐ **Yes**

☐ **No**

**115. Hydroxyurea (Droxia, Hydrea)**

☐ **Yes**

☐ **No**

**116. Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)**

☐ **Yes**

☐ **No**

**117. Interferon-α (Intron, Roferon) (includes PEG)**

☐ **Yes**

☐ **No**

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

118. Other therapy

☐ Yes - **Go to question 118**

☐ No - **Go to question 119**

119. Specify other therapy: \_\_\_\_\_

~~120.~~ What was the disease status~~What was the disease status at last evaluation prior to the start of the preparative regimen?~~

☐ Complete hematologic response~~mission (CHR)~~ - **Go to questions ~~120~~120**

☐ ~~C~~First chronic phase – **Go to question ~~124~~120**

☐ ~~Second or greater chronic phase~~ – **Go to question ~~123~~**

☐ Accelerated phase - **Go to question ~~121~~13**

☐ Blast crisis - **Go to question ~~121~~13**

**Specify remission:**

~~121.~~ Cytogenetic complete remission (Ph-negative)Specify level of response

☐ No cytogenetic response (No CyR)

☐ Minimal cytogenetic response

☐ Minor cytogenetic response

☐ Partial cytogenetic response (PCyR)

☐ Major cytogenetic response (MCyR)

☐ Complete cytogenetic response (CCyR)

☐ Major molecular remission (MMR)

☐ Complete molecular remission (CMR) ☐ Yes

☐ No

☐ Unknown

~~122.~~ Molecular complete remission (BCR / ABL-negative)

☐ Yes

☐ No

☐ Unknown

~~123.~~ CML disease status before treatment that achieved this CR:

☐ Chronic phase – **Go to question ~~124~~**

☐ Accelerated phase – **Go to question ~~124~~**

☐ Blast phase – **Go to question ~~124~~**

~~124.~~ Number

☐ 1st

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

- ☐ 2nd  
☐ 3rd or higher

125. Date assessed: \_\_\_\_\_ - **Go to signature line**  
                                        YYYY                        MM                        DD

### Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases

126. What was the MDS / MPN subtype at diagnosis? – **If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification questions**

- ☐ Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)
- ☐ Refractory anemia with ringed sideroblasts (RARS) (55)
- ☐ Refractory anemia with excess blasts-1 (RAEB-1) (61)
- ☐ Refractory anemia with excess blasts-2 (RAEB-2) (62)
- ☐ Refractory cytopenia with multilineage dysplasia (RCMD) (64)
- ☐ Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)
- ☐ Myelodysplastic syndrome with isolated del(5q) (5q- syndrome) (66)
- ☐ Myelodysplastic syndrome (MDS), unclassifiable (50)
- ☐ Chronic neutrophilic leukemia (165)
- ☐ Chronic eosinophilic leukemia, NOS (166)
- ☐ Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)
- ☐ Polycythemia vera (PCV) (57)
- ☐ Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia (MMM), idiopathic myelofibrosis) (167)
- ☐ Myeloproliferative neoplasm (MPN), unclassifiable (60)
- ☐ Chronic myelomonocytic leukemia (CMML) (54)
- ☐ Juvenile myelomonocytic leukemia (JMML/JCML) (no evidence of Ph<sup>1</sup> or BCR/ABL) (36) – **Go to question 168525**
- ☐ Atypical chronic myeloid leukemia, Ph-/bcr/abl- {CML, NOS} (45) - **Go to question 577222**
- ☐ Atypical chronic myeloid leukemia, Ph-/bcr unknown {CML, NOS} (46) - **Go to question 577222**
- ☐ Atypical chronic myeloid leukemia, Ph unknown/bcr- {CML, NOS} (48) - **Go to question 577222**
- ☐ Atypical chronic myeloid leukemia, Ph unknown/bcr unknown {CML, NOS} (49) - **Go to question 577222**
- ☐ Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69)

127. Was the disease (MDS/MPN) therapy related?

- ☐ Yes  
☐ No  
☐ Unknown

128. Did the recipient have a predisposing condition?

- ☐ Yes – **Go to question 1268**  
☐ No – **Go to question 12830**  
☐ Unknown – **Go to question 12830**

129. Specify condition:

- ☐ Aplastic anemia – **Go to question 12830**  
☐ Bloom syndrome – **Go to question 12830**  
☐ Down syndrome – **Go to question 12830**  
☐ Fanconi anemia – **Go to question 12830**  
☐ Other condition – **Go to question 1279**

130. Specify other condition: \_\_\_\_\_

#### Laboratory Studies at Diagnosis of MDS

131. WBC

- ☐ Known  
☐ Unknown

132. \_\_\_\_\_ • \_\_\_\_\_  $\times 10^9/L$  ( $\times 10^3/mm^3$ )  
\_\_\_\_\_  $\times 10^6/L$

133. Hemoglobin

- ☐ Known  
☐ Unknown

134. \_\_\_\_\_ • \_\_\_\_\_  $g/dL$   
\_\_\_\_\_  $g/L$   
\_\_\_\_\_  $mmol/L$

135. Was RBC transfused  $\leq 30$  days before date of test?

- ☐ Yes  
☐ No

136. Platelets

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ Known

☐ Unknown

137. \_\_\_\_\_ ☐ x 10<sup>9</sup>/L (x 10<sup>3</sup>/mm<sup>3</sup>)  
\_\_\_\_\_ ☐ x 10<sup>6</sup>/L

138. Were platelets transfused ≤ 7 days before date of test?

☐ Yes

☐ No

139. Neutrophils

☐ Known

☐ Unknown

140. \_\_\_\_\_ %

141. Blasts in bone marrow

☐ Known

☐ Unknown

142. \_\_\_\_\_ %

143. Were cytogenetics tested (karyotyping or FISH)?

☐ Yes – **Go to question 1413**

☐ No – **Go to question 16870**

☐ Unknown – **Go to question 1687**

144. Results of tests:

☐ Abnormalities identified – **Go to question 1424**

☐ No evaluable metaphases – **Go to question 16870**

☐ No abnormalities – **Go to question 16870**

**Specify abnormalities identified at diagnosis:**

145. Specify number of distinct cytogenetic abnormalities:

☐ One (1)

☐ Two (2)

☐ Three (3)

☐ Four or more (4 or more)

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

### Monosomy

146. -5  
☐ Yes  
☐ No
147. -7  
☐ Yes  
☐ No
148. -13  
☐ Yes  
☐ No
149. -20  
☐ Yes  
☐ No
150. -Y  
☐ Yes  
☐ No

### Trisomy

151. +8  
☐ Yes  
☐ No
152. +19  
☐ Yes  
☐ No

### Translocation

153. t(1;3)  
☐ Yes  
☐ No
154. t(2;11)  
☐ Yes

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ No

155. t(3;3)

☐ Yes

☐ No

156. t(3;21)

☐ Yes

☐ No

157. t(6;9)

☐ Yes

☐ No

158. t(11;16)

☐ Yes

☐ No

#### Deletion

159. del(3q) / 3q-

☐ Yes

☐ No

160. del(5q) / 5q-

☐ Yes –

☐ No

161. del(7q) / 7q-

☐ Yes

☐ No

162. del(9q) / 9q-

☐ Yes

☐ No

163. del(11q) / 11q-

☐ Yes

☐ No

164. del(12p) / 12p-



CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ Yes

☐ No

165. del(13q) / 13q-

☐ Yes

☐ No

166. del(20q) / 20q-

☐ Yes

☐ No

#### **Inversion**

167. inv(3)

☐ Yes

☐ No

#### **Other**

168. i17q

☐ Yes

☐ No

169. Other abnormality

☐ Yes – **Go to question 1679**

☐ No – **Go to question 16870**

170. Specify other abnormality: \_\_\_\_\_

171. Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

☐ Yes – **Go to question 16971**

☐ No – **Go to question 1724**

172. Specify the MDS / MPN subtype after transformation:

☐ Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51) – **Go to question 1702**

☐ Refractory anemia with ringed sideroblasts (RARS) (55) – **Go to question 1702**

☐ Refractory anemia with excess blasts-1 (RAEB-1) (61) – **Go to question 1702**

☐ Refractory anemia with excess blasts-2 (RAEB-2) (62) – **Go to question 1702**

- ☐ Refractory cytopenia with multilineage dysplasia (RCMD) (64) – **Go to question 1702**
- ☐ Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68) – **Go to question 1702**
- ☐ Myelodysplastic syndrome with isolated del(5q) (5q– syndrome) (66) – **Go to question 1702**
- ☐ Myelodysplastic syndrome (MDS), unclassifiable (50) – **Go to question 1702**
- ☐ Chronic neutrophilic leukemia (165) – **Go to question 1702**
- ☐ Chronic eosinophilic leukemia, NOS (166) – **Go to question 1702**
- ☐ Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58) – **Go to question 1702**
- ☐ Polycythemia vera (PCV) (57) – **Go to question 1702**
- ☐ Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia (MMM), idiopathic myelofibrosis) (167) – **Go to question 1702**
- ☐ Myeloproliferative neoplasm (MPN), unclassifiable (60) – **Go to question 1702**
- ☐ Chronic myelomonocytic leukemia (CMML) (54) – **Go to question 1702**
- ☐ Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69) – **Go to question 1702**
- ☐ Transformed to AML (70) – **Go to question 1713.**

173. Specify the date of the most recent transformation: \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_ -

**Go to question 1724**

174. ~~Date of MDS diagnosis: \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_~~ – **Go to signature line** Date of MDS diagnosis: \_\_\_\_\_  
\_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_ – **Go to signature line**

**Laboratory studies at last evaluation prior to the start of the preparative regimen:**

175. WBC

- ☐ Known
- ☐ Unknown

176. \_\_\_\_\_ • \_\_\_\_\_ ☐ x 10<sup>9</sup>/L (x 10<sup>3</sup>/mm<sup>3</sup>)  
\_\_\_\_\_ ☐ x 10<sup>6</sup>/L

177. Hemoglobin

- ☐ Known
- ☐ Unknown

178. \_\_\_\_\_ • \_\_\_\_\_ ☐ g/dL  
\_\_\_\_\_ ☐ g/L

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

☐ mmol/L

179. Was RBC transfused  $\leq 30$  days before date of test?

☐ Yes

☐ No

180. Platelets

☐ Known

☐ Unknown

181. \_\_\_\_\_ ☐  $\times 10^9/L$  ( $\times 10^3/mm^3$ )

☐  $\times 10^6/L$

182. Were platelets transfused  $\leq 7$  days before date of test?

☐ Yes

☐ No

183. Neutrophils

☐ Known

☐ Unknown

184. \_\_\_\_\_ %

185. Blasts in bone marrow

☐ Known

☐ Unknown

186. \_\_\_\_\_ %

187. Were cytogenetics tested (karyotyping or FISH)?

☐ Yes – **Go to question 1858**

☐ No – **Go to question 2125**

☐ Unknown – **Go to question 2125**

188. Results of tests:

☐ Abnormalities identified – **Go to question 1869**

☐ No evaluable metaphases – **Go to question 2125**

☐ No abnormalities – **Go to question 2125**

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

**Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:**

189. Specify number of distinct cytogenetic abnormalities:

- ☐ One (1)  
☐ Two (2)  
☐ Three (3)  
☐ Four or more (4 or more)

**Monosomy**

190. -5

- ☐ Yes  
☐ No

191. -7

- ☐ Yes  
☐ No

192. -13

- ☐ Yes  
☐ No

193. -20

- ☐ Yes  
☐ No

194. -Y

- ☐ Yes  
☐ No

**Trisomy**

195. +8

- ☐ Yes  
☐ No

196. +19

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ Yes

☐ No

### Translocation

197. t(1;3)

☐ Yes

☐ No

198. t(2;11)

☐ Yes

☐ No

199. t(3;3)

☐ Yes

☐ No

200. t(3;21)

☐ Yes

☐ No

201. t(6;9)

☐ Yes

☐ No

202. t(11;16)

☐ Yes

☐ No

### Deletion

203. del(3q) / 3q-

☐ Yes

☐ No

204. del(5q) / 5q-

☐ Yes

☐ No

205. del(7q) / 7q-

☐ Yes

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ No

206. del(9q) / 9q-

☐ Yes

☐ No

207. del(11q) / 11q-

☐ Yes

☐ No

208. del(12p) / 12p-

☐ Yes

☐ No

209. del(13q) / 13q-

☐ Yes

☐ No

210. del(20q) / 20q-

☐ Yes

☐ No

#### **Inversion**

211. inv(3)

☐ Yes

☐ No

#### **Other**

212. i17q

☐ Yes

☐ No

213. Other abnormality

☐ Yes – **Go to question 2114**

☐ No – **Go to question 2125**

214. Specify other abnormality: \_\_\_\_\_

#### **Status at Transplantation**

215. What was the disease status?

- ☐ ☐ Complete remission (CR) – requires all of the following, maintained for  $\geq 4$  weeks: \* bone marrow evaluation:  $< 5\%$  myeloblasts with normal maturation of all cell lines \* peripheral blood evaluation: hemoglobin  $\geq 11$  g/dL untransfused and without erythropoietin support; ANC  $\geq 1000$  / mm<sup>3</sup> without myeloid growth factor support; platelets  $\geq 100 \times 10^9$ /L without thrombopoietic support; 0% blasts - **Go to question 2169**
- ☐ ☐ Hematologic improvement (HI) – requires one measurement of the following, maintained for  $\geq 8$  weeks without ongoing cytotoxic therapy; specify which cell line was measured to determine HI response: \* HI-E – hemoglobin increase of  $\geq 1.5$  g/dL untransfused; for RBC transfusions performed for Hgb  $\leq 9.0$ , reduction in RBC units transfused in 8 weeks by  $\geq 4$  units compared to the pre-treatment transfusion number in 8 weeks \* HI-P – for pre-treatment platelet count of  $> 20 \times 10^9$ /L, platelet absolute increase of  $\geq 30 \times 10^9$ /L; for pre-treatment platelet count of  $< 20 \times 10^9$ /L, platelet absolute increase of  $\geq 20 \times 10^9$ /L and  $\geq 100\%$  from pre-treatment level \* HI-N – neutrophil count increase of  $\geq 100\%$  from pre-treatment level and an absolute increase of  $\geq 500$  / mm<sup>3</sup> - **Go to question 2136**
- ☐ No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression - **Go to question 2169**
- ☐ ☐ Progression from hematologic improvement (Prog from HI) – requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): \*  $\geq 50\%$  reduction from maximum response levels in granulocytes or platelets \* reduction in hemoglobin by  $\geq 1.5$  g/dL \*transfusion dependence - **Go to question 2147**
- ☐ ☐ Relapse from complete remission (Rel from CR) – requires at least one of the following: \* return to pre-treatment bone marrow blast percentage \* decrease of  $\geq 50\%$  from maximum response levels in granulocytes or platelets \* transfusion dependence, or hemoglobin level  $\geq 1.5$  g/dL lower than prior to therapy - **Go to question 2158**
- ☐ ☐ Not assessed - **Go to signature line**

216. Specify the cell line examined to determine HI status:

- ☐ ☐ HI-E – hemoglobin increase of  $\geq 1.5$  g/dL transfused; for RBC transfusions performed for Hgb  $\leq 9.0$ , reduction in RBC units transfused in 8 weeks by  $\geq 4$  units compared to the pre-treatment transfusion number in 8 weeks - **Go to question 2169**
- ☐ ☐ HI-P – for pre-treatment platelet count of  $> 20 \times 10^9/L$ , platelet absolute increase of  $\geq 30 \times 10^9/L$ ; for pre-treatment platelet count of  $< 20 \times 10^9/L$ , platelet absolute increase of  $\geq 20 \times 10^9/L$  and  $\geq 100\%$  from pre-treatment level – **Go to question 2169**
- ☐ ☐ HI-N – neutrophil count increase of  $\geq 100\%$  from pre-treatment level and an absolute increase of  $\geq 500 / mm^3$  - **Go to question 2169**

217. Date of progression: \_\_\_\_ - \_\_\_\_ - \_\_\_\_ - **Go to question 2169**  
 YYYY MM DD

218. Date of relapse: \_\_\_\_ - \_\_\_\_ - \_\_\_\_ - **Go to question 2169**  
 YYYY MM DD

219. Date assessed: \_\_\_\_-\_\_\_\_-\_\_\_\_ - **Go to signature line**  
YYYY MM DD

**Other Leukemia (OL)**

220. Specify the other leukemia classification:

- ☐ Chronic lymphocytic leukemia (CLL), NOS (34) - **Go to question 575219**
- ☐ Chronic lymphocytic leukemia (CLL), B-cell / small lymphocytic lymphoma (SLL) (71) - **Go to question 575219**
- ☐ Hairy cell leukemia (35) - **Go to question 578221**
- ☐ Hairy cell leukemia variant (75) - **Go to question 578221**
- ☐ Monoclonal B-cell lymphocytosis (76) – **Go to signature line**
- ☐ Prolymphocytic leukemia (PLL), NOS (37) - **Go to question 575219**
- ☐ PLL, B-cell (73) - **Go to question 575219**
- ☐ PLL, T-cell (74) - **Go to question 575219**
- ☐ Other leukemia, NOS (30) - **Go to question 577220**
- ☐ Other leukemia (39) - **Go to question 218574**

221. Specify other leukemia: \_\_\_\_\_ – **Go to question 577220**

222. Was any 17p abnormality detected?

- ☐ Yes – **If disease classification is CLL, go to question 2202. If PLL, go to question 2213.**
- ☐ No

223. Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?

- ☐ Yes – **Go to question 583227– Also complete NHL Disease Classification questions**
- ☐ No – **Go to question 578222**

**Status at transplantation:**

224. What was the disease status? (Atypical CML)

- ☐ Primary induction failure – **Go to question 579223**
- ☐ 1st complete remission (no previous bone marrow or extramedullary relapse) – **Go to question 579223**
- ☐ 2nd complete remission – **Go to question 579223**
- ☐ ≥ 3rd complete remission – **Go to question 579223**
- ☐ 1st relapse – **Go to question 579223**
- ☐ 2nd relapse – **Go to question 579223**
- ☐ ≥ 3rd relapse – **Go to question 579223**
- ☐ No treatment – **Go to signature line**



CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

225. What was the disease status? (CLL, PLL, Hairy cell leukemia)

- ☐ Complete remission (CR)
- ☐ Partial remission (PR)
- ☐ Stable disease (SD)
- ☐ Progressive disease (Prog)
- ☐ Untreated
- ☐ Not assessed - **Go to signature line**

226. Date assessed: \_\_\_\_\_ - **Go to signature line**  
                                        YYYY                        MM                        DD

### Hodgkin Lymphoma

227. Specify Hodgkin lymphoma classification:

- ☐ Nodular lymphocyte predominant Hodgkin lymphoma (155)
- ☐ Lymphocyte-rich (151)
- ☐ Nodular sclerosis (152)
- ☐ Mixed cellularity (153)
- ☐ Lymphocyte depleted (154)
- ☐ Hodgkin lymphoma, NOS (150)

### Status at transplantation:

228. What was the disease status?

- ☐ Disease untreated
- ☐ PIF res - Primary induction failure – resistant: NEVER in COMPLETE remission but with stable or progressive disease on treatment.
- ☐ PIF sen / PR1 - Primary induction failure – sensitive: NEVER in COMPLETE remission but with partial remission on treatment.
- ☐ PIF unk - Primary induction failure – sensitivity unknown
- ☐ CR1 - 1<sup>st</sup> complete remission: no bone marrow or extramedullary relapse prior to transplant
- ☐ CR2 - 2<sup>nd</sup> complete remission
- ☐ CR3+ - 3<sup>rd</sup> or subsequent complete remission
- ☐ REL1 unt - 1<sup>st</sup> relapse – untreated; includes either bone marrow or extramedullary relapse
- ☐ REL1 res - 1<sup>st</sup> relapse – resistant: stable or progressive disease with treatment
- ☐ REL1 sen - 1<sup>st</sup> relapse – sensitive: partial remission (if complete remission was achieved, classify as CR2)
- ☐ REL1 unk - 1<sup>st</sup> relapse – sensitivity unknown

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

- ☐ REL2 unt - 2<sup>nd</sup> relapse – untreated: includes either bone marrow or extramedullary relapse
- ☐ REL2 res - 2<sup>nd</sup> relapse – resistant: stable or progressive disease with treatment
- ☐ REL2 sen - 2<sup>nd</sup> relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)
- ☐ REL2 unk - 2<sup>nd</sup> relapse – sensitivity unknown
- ☐ REL3+ unt - 3<sup>rd</sup> or subsequent relapse – untreated; includes either bone marrow or extramedullary relapse
- ☐ REL3+ res - 3<sup>rd</sup> or subsequent relapse – resistant: stable or progressive disease with treatment
- ☐ REL3+ sen - 3<sup>rd</sup> or subsequent relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)
- ☐ REL3+ unk - 3<sup>rd</sup> relapse or greater – sensitivity unknown

229. Date assessed: \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_ - **Go to signature line**  
                                YYYY                MM                DD

### Non-Hodgkin Lymphoma

230. \_\_\_\_\_ Specify Non-Hodgkin lymphoma classification:

- ☐ Splenic marginal zone B-cell lymphoma (124)
- ☐ Extranodal marginal zone B-cell lymphoma of mucosal associated lymphoid tissue type (MALT) (122)
- ☐ Nodal marginal zone B-cell lymphoma (± monocytoid B-cells) (123)
- ☐ Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma) (102)
- ☐ Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma) (103)
- ☐ Follicular, predominantly large cell (Grade IIIA follicle center lymphoma) (162)
- ☐ Follicular, predominantly large cell (Grade IIIB follicle center lymphoma) (163)
- ☐ Follicular (grade unknown) (164)
- ☐ Mantle cell lymphoma (115)
- ☐ Intravascular large B-cell lymphoma (136)
- ☐ Primary mediastinal (thymic) large B-cell lymphoma (125)
- ☐ Primary effusion lymphoma (138)
- ☐ Diffuse, large B-cell lymphoma — NOS (107)
- ☐ Burkitt lymphoma (111)
- ☐ B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (140)
- ☐ B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin Lymphoma (149)
- ☐ T-cell / histiocytic rich large B-cell lymphoma (120)
- ☐ Primary diffuse large B-cell lymphoma of the CNS (118)

- ☐ Waldenstrom macroglobulinemia / Lymphoplasmacytic lymphoma (173)
- ☐ Other B-cell lymphoma (129) – **Go to question 584228**
- ☐ Extranodal NK / T-cell lymphoma, nasal type (137)
- ☐ Enteropathy-type T-cell lymphoma (133)
- ☐ Hepatosplenic T-cell lymphoma (145)
- ☐ Subcutaneous panniculitis-like T-cell lymphoma (146)
- ☐ Mycosis fungoides (141)
- ☐ Sezary syndrome (142)
- ☐ Primary cutaneous CD30+ T-cell lymphoproliferative disorders [Primary cutaneous anaplastic large-cell lymphoma (C-ALCL), lymphoid papulosis] (147)
- ☐ Peripheral T-cell lymphoma (PTCL), NOS (130)
- ☐ Angioimmunoblastic T-cell lymphoma (131)
- ☐ Anaplastic large-cell lymphoma (ALCL), ALK positive (143)
- ☐ Anaplastic large-cell lymphoma (ALCL), ALK negative (144)
- ☐ T-cell large granular lymphocytic leukemia (126)
- ☐ Aggressive NK-cell leukemia (27)
- ☐ Adult T-cell lymphoma / leukemia (HTLV1 associated) (134)
- ☐ Other T-cell / NK-cell lymphoma (139) – **Go to question 584228**

231. Specify other lymphoma: \_\_\_\_\_

232. Is the non-Hodgkin lymphoma histology reported at diagnosis a transformation from CLL?

- ☐ Yes – **Go to question 587231- Also complete CLL Disease Classification questions**
- ☐ No - **Go to question 586230**

233. Is the non-Hodgkin lymphoma histology reported a transformation from, or was it diagnosed at the same time as another lymphoma (not CLL)?

- ☐ Yes
- ☐ No

#### Status at Transplantation

234. What was the disease status?

- ☐ Disease untreated
- ☐ PIF res - Primary induction failure – resistant: NEVER in COMPLETE remission but with stable or progressive disease on treatment.
- ☐ PIF sen / PR1 - Primary induction failure – sensitive: NEVER in COMPLETE remission but with partial remission on treatment.
- ☐ PIF unk - Primary induction failure – sensitivity unknown

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

- ☐ ☐ CR1 - 1<sup>st</sup> complete remission: no bone marrow or extramedullary relapse prior to transplant
- ☐ ☐ CR2 - 2<sup>nd</sup> complete remission
- ☐ ☐ CR3+ - 3<sup>rd</sup> or subsequent complete remission
- ☐ ☐ REL1 unt - 1<sup>st</sup> relapse – untreated; includes either bone marrow or extramedullary relapse
- ☐ ☐ REL1 res - 1<sup>st</sup> relapse – resistant: stable or progressive disease with treatment
- ☐ ☐ REL1 sen - 1<sup>st</sup> relapse – sensitive: partial remission (if complete remission was achieved, classify as CR2)
- ☐ ☐ REL1 unk - 1<sup>st</sup> relapse – sensitivity unknown
- ☐ ☐ REL2 unt - 2<sup>nd</sup> relapse – untreated: includes either bone marrow or extramedullary relapse
- ☐ ☐ REL2 res - 2<sup>nd</sup> relapse – resistant: stable or progressive disease with treatment
- ☐ ☐ REL2 sen - 2<sup>nd</sup> relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)
- ☐ ☐ REL2 unk - 2<sup>nd</sup> relapse – sensitivity unknown
- ☐ ☐ REL3+ unt - 3<sup>rd</sup> or subsequent relapse – untreated; includes either bone marrow or extramedullary relapse
- ☐ ☐ REL3+ res - 3<sup>rd</sup> or subsequent relapse – resistant: stable or progressive disease with treatment
- ☐ ☐ REL3+ sen - 3<sup>rd</sup> or subsequent relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)
- ☐ ☐ REL3+ unk - 3<sup>rd</sup> relapse or greater – sensitivity unknown

235. Date assessed: \_\_\_\_\_ - **Go to signature line**  
                                        YYYY                        MM                        DD

#### Multiple Myeloma / Plasma Cell Disorder (PCD)

236. \_\_\_\_\_ Specify the multiple myeloma/plasma cell disorder (PCD) classification:

- ☐ Multiple myeloma-IgG (181) - **Go to questions [591235](#)**
- ☐ Multiple myeloma-IgA (182) - **Go to questions [235591](#)**
- ☐ Multiple myeloma-IgD (183) - **Go to questions [235591](#)**
- ☐ Multiple myeloma-IgE (184) - **Go to questions [235591](#)**
- ☐ Multiple myeloma-IgM (not Waldenstrom macroglobulinemia) (185) - **Go to questions [235591](#)**
- ☐ Multiple myeloma-light chain only (186) - **Go to questions [235591](#)**
- ☐ Multiple myeloma-non-secretory (187) - **Go to questions [592236](#)**
- ☐ Plasma cell leukemia (172) - **Go to question [597241](#)**
- ☐ Solitary plasmacytoma (no evidence of myeloma) (175) - **Go to question [241597](#)**
- ☐ Amyloidosis (174) - **Go to question [241597](#)**
- ☐ Osteosclerotic myeloma / POEMS syndrome (176) - **Go to questions [241597](#)**

☐ Light chain deposition disease (177) - **Go to questions 241597**

☐ Other plasma cell disorder (179) - **Go to question 590234**

237. Specify other plasma cell disorder: \_\_\_\_\_ - **Go to question 241597**

238. \_\_\_\_\_ Light chain

☐ kappa

☐ lambda

239. What was the Durie-Salmon staging (at diagnosis)?

☐ Stage I (All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma only; low M-component production rates IgG < 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4g/24h) – **Go to questions 593237**

☐ Stage II (Fitting neither Stage I or Stage III) – **Go to questions 593237**

☐ Stage III (One of more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates IgG >7g/dL, IgA > 5g/dL; Bence Jones protein >12g/24h) – **Go to questions 593237**

☐ Unknown – **Go to questions 594238**

240. What was the Durie-Salmon sub classification (at diagnosis)?

☐ A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

☐ B - abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

#### I.S.S.:

241. Serum  $\beta_2$ -microglobulin: \_\_\_\_\_ • \_\_\_\_\_  
\_\_\_\_\_ ☐  $\mu$ g/dL

☐ mg/L

☐ nmol/L

242. Serum albumin: \_\_\_\_\_ • \_\_\_\_\_ ☐ g/dL  
☐ g/L

243. Stage

☐ 1 ( $\beta_2$ -mic < 3.5, S. albumin > 3.5)

☐ 2 ( $\beta_2$ -mic 3.5–< 5.5, S. albumin —)

☐ 3 ( $\beta_2$ -mic ≥ 5.5; S. albumin —)

244. Were cytogenetics tested (karyotyping or FISH)?

☐ Yes – **Go to questions 598242**

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ ☐ No – **Go to question [619263](#)**

☐ ☐ Unknown – **Go to question [619 263](#)**

245. Results of tests:

☐ ☐ Abnormalities identified – **Go to question [599243](#)**

☐ ☐ No evaluable metaphases – **Go to question [619263](#)**

☐ ☐ No abnormalities – **Go to question [619263](#)**

**Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:**

**Trisomy**

246. +3

☐ ☐ Yes

☐ ☐ No

247. +5

☐ ☐ Yes

☐ ☐ No

248. +7

☐ ☐ Yes

☐ ☐ No

249. +9

☐ ☐ Yes

☐ ☐ No

250. +11

☐ ☐ Yes

☐ ☐ No

251. +15

☐ ☐ Yes

☐ ☐ No

252. +19

☐ ☐ Yes

☐ ☐ No

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

### Translocation

253. t(4;14)

☐ Yes

☐ No

254. t(6;14)

☐ Yes

☐ No

255. t(11;14)

☐ Yes

☐ No

256. t(14;16)

☐ Yes

☐ No

257. t(14;20)

☐ Yes

☐ No

### Deletion

258. del 13/13q-

☐ Yes

☐ No

259. del 17/17p-

☐ Yes

☐ No

### Other

260. Hyperdiploid (>50)

☐ Yes

☐ No

261. Hypodiploid (<46)

☐ Yes

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ ☐ No

262. Any abnormality at 1q

☐ ☐ Yes

☐ ☐ No

263. Any abnormality at 1p

☐ ☐ Yes

☐ ☐ No

264. Other abnormality

☐ ☐ Yes — **Go to question 618**

☐ ☐ No — **Go to question 619**

265. Specify other abnormality: \_\_\_\_\_

#### Status at transplantation:

266. \_\_\_\_\_ What was the disease status?

☐ ☐ ☐ **Stringent complete remission (sCR).** - CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the  $\kappa/\lambda$  ratio. An abnormal  $\kappa/\lambda$  ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is  $\kappa/\lambda$  of  $> 4:1$  or  $< 1:2$ .) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR requirements.

☐ ☐ ☐ **Complete remission (CR)** — negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and  $\leq 5\%$  plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). CR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy CR requirements.

☐ ☐ ☐ **Near complete remission (nCR)** — serum & urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP);  $\leq 5\%$  plasma cells in bone marrow. nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements.

☐ ☐ ☐ **Very good partial remission (VGPR)** — serum and urine M-protein detectable by immunofixation but not on electrophoresis, or  $\geq 90\%$  reduction in serum M-protein and urine M-protein level  $< 100$  mg/24 hours. VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

☐ ☐ ☐ **Partial remission (PR)** —  $\geq 50\%$  reduction in serum M-protein, and reduction in 24-hour urinary M-protein by  $\geq 90\%$  or to  $< 200$  mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: • serum M-protein  $\geq 1$  g/dL. Urine M-protein  $\geq 200$  mg/24 hours • serum free light chain assay shows involved level  $\geq 10$  mg/dL, provided serum free light chain ratio is abnormal), a  $\geq 50\%$  decrease in



CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a  $\geq 50\%$  reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was  $\geq 30\%$ . In addition to the above listed criteria, a  $\geq 50\%$  reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements.

☐ ☐ ☐ **Stable disease (SD)** — not meeting the criteria for CR, VGPR, PR or PD. SD requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD requirements.

☐ ☐ ☐ **Progressive disease (PD)** — requires any one or more of the following: Increase of  $\geq 25\%$  from baseline in: serum M-component and/or (absolute increase  $\geq 0.5$  g/dL) (for progressive disease, serum M-component increases of  $\geq 1$  g/dL are sufficient to define relapse if the starting M-component is  $\geq 5$  g/dL). Urine M-component and/or (absolute increase  $\geq 200$  mg/24 hours) for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase  $> 10$  mg/dL). Bone marrow plasma cell percentage (absolute percentage  $\geq 10\%$ ) (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium  $> 11.5$  mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder PD requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy

☐ ☐ **Relapse from CR (Rel) (untreated)** — requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis development of  $\geq 5\%$  plasma cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia) Rel requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.

☐ **Unknown**

☐ **Not applicable** (Amyloidosis with no evidence of myeloma)

267. Date assessed: \_\_\_\_\_ - **Go to signature line**

YYYY

MM

DD

### Solid Tumors

268. Specify the solid tumor classification:

☐ ☐ Breast cancer (250)

☐ ☐ Lung, small cell (202)

☐ Lung, non-small cell (203)

☐ Lung, not otherwise specified (230)

☐ Germ cell tumor, extragonadal (225)

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

- ☐ Testicular (210)
- ☐ Ovarian (epithelial) (214)
- ☐ Bone sarcoma (excluding Ewing family tumors) (273)
- ☐ Ewing family tumors of bone (including PNET) (275)
- ☐ Ewing family tumors, extraosseous (including PNET) (276)
- ☐ Fibrosarcoma (244)
- ☐ Hemangiosarcoma (246)
- ☐ Leiomyosarcoma (242)
- ☐ Liposarcoma (243)
- ☐ Lymphangio sarcoma (247)
- ☐ Neurogenic sarcoma (248)
- ☐ Rhabdomyosarcoma (232)
- ☐ Synovial sarcoma (245)
- ☐ Soft tissue sarcoma (excluding Ewing family tumors) (274)
- ☐ Central nervous system tumor, including CNS PNET (220)
- ☐ Medulloblastoma (226)
- ☐ Neuroblastoma (222)
- ☐ Head / neck (201)
- ☐ Mediastinal neoplasm (204)
- ☐ Colorectal (228)
- ☐ Gastric (229)
- ☐ Pancreatic (206)
- ☐ Hepatobiliary (207)
- ☐ Prostate (209)
- ☐ External genitalia (211)
- ☐ Cervical (212)
- ☐ Uterine (213)
- ☐ Vaginal (215)
- ☐ Melanoma (219)
- ☐ Wilm tumor (221)
- ☐ Retinoblastoma (223)
- ☐ Thymoma (231)
- ☐ Renal cell (208)
- ☐ Other solid tumor (269) – **Go to question [622266](#)**
- ☐ Solid tumor, not otherwise specified (200)

269. Specify other solid tumor: \_\_\_\_\_

- **Go to signature line**

### Severe Aplastic Anemia

270. Specify the severe aplastic anemia classification:

- ☐ Acquired severe aplastic anemia, not otherwise specified (301)
- ☐ Acquired SAA secondary to hepatitis (302)
- ☐ Acquired SAA secondary to toxin / other drug (303)
- ☐ Acquired amegakaryocytosis (not congenital) (304)
- ☐ Acquired pure red cell aplasia (not congenital) (306)
- ☐ Dyskeratosis congenita (307)
- ☐ Other acquired cytopenic syndrome (309) – **Go to question [624268](#)**

271. Specify other acquired cytopenic syndrome: \_\_\_\_\_

- **Go to signature line**

### Inherited Abnormalities of Erythrocyte Differentiation or Function

272. Specify the inherited abnormalities of erythrocyte differentiation or function classification:

- ☐ Paroxysmal nocturnal hemoglobinuria (PNH) (56)
- ☐ Shwachman-Diamond (305)
- ☐ Diamond-Blackfan anemia (pure red cell aplasia) (312)
- ☐ Other constitutional anemia (319) – **Go to question [626270](#)**
- ☐ Fanconi anemia (311) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease).
- ☐ Sickle thalassemia (355)
- ☐ Sickle cell disease (356)
- ☐ Beta thalassemia major (357)
- ☐ Other hemoglobinopathy (359) – **Go to question [627271](#)**

273. Specify other constitutional anemia: \_\_\_\_\_

274. Specify other hemoglobinopathy: \_\_\_\_\_

- **Go to signature line**

### Disorders of the Immune System

275. Specify disorder of immune system classification:

- ☐ Adenosine deaminase (ADA) deficiency / severe combined immunodeficiency (SCID) (401)
- ☐ Absence of T and B cells SCID (402)
- ☐ Absence of T, normal B cell SCID (403)
- ☐ Omenn syndrome (404)
- ☐ Reticular dysgenesis (405)
- ☐ Bare lymphocyte syndrome (406)
- ☐ Other SCID (419) – **Go to question 629273**
- ☐ SCID, not otherwise specified (410)
- ☐ Ataxia telangiectasia (451)
- ☐ HIV infection (452)
- ☐ DiGeorge anomaly (454)
- ☐ Common variable immunodeficiency (457)
- ☐ Leukocyte adhesion deficiencies, including GP180, CD-18, LFA and WBC adhesion deficiencies (459)
- ☐ Kostmann agranulocytosis (congenital neutropenia) (460)
- ☐ Neutrophil actin deficiency (461)
- ☐ Cartilage-hair hypoplasia (462)
- ☐ CD40 ligand deficiency (464)
- ☐ Other immunodeficiencies (479) – **Go to question 630274**
- ☐ Immune deficiency, not otherwise specified (400)
- ☐ Chediak-Higashi syndrome (456)
- ☐ Griscelli syndrome type 2 (465)
- ☐ Hermansky-Pudlak syndrome type 2 (466)
- ☐ Chronic granulomatous disease (455)
- ☐ Wiskott-Aldrich syndrome (453)
- ☐ X-linked lymphoproliferative syndrome (458)

276. Specify other SCID: \_\_\_\_\_

277. Specify other immunodeficiency: \_\_\_\_\_

- **Go to signature line**

#### Inherited Abnormalities of Platelets

278. Specify inherited abnormalities of platelets classification:

- ☐ Congenital amegakaryocytosis / congenital thrombocytopenia (501)
- ☐ Glanzmann thrombasthenia (502)
- ☐ Other inherited platelet abnormality (509) – **Go to question [277276](#)**

279. Specify other inherited platelet abnormality: \_\_\_\_\_

- **Go to signature line**

#### Inherited Disorders of Metabolism

280. Specify inherited disorders of metabolism classification:

- ☐ Osteopetrosis (malignant infantile osteopetrosis) (521)

##### **Leukodystrophies**

- ☐ Metachromatic leukodystrophy (MLD) (542)
- ☐ Adrenoleukodystrophy (ALD) (543)
- ☐ Krabbe disease (globoid leukodystrophy) (544)
- ☐ Lesch-Nyhan (HGPRT deficiency) (522)
- ☐ Neuronal ceroid lipofuscinosis (Batten disease) (523)

##### **Mucopolysaccharidoses**

- ☐ Hurler syndrome (IH) (531)
- ☐ Scheie syndrome (IS) (532)
- ☐ Hunter syndrome (II) (533)
- ☐ Sanfilippo (III) (534)
- ☐ Morquio (IV) (535)
- ☐ Maroteaux-Lamy (VI) (536)
- ☐  $\beta$ -glucuronidase deficiency (VII) (537)
- ☐ Mucopolysaccharidosis (V) (538)
- ☐ Mucopolysaccharidosis, not otherwise specified (530)

##### **Mucolipidoses**

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

- ☐ Gaucher disease (541)
- ☐ Niemann-Pick disease (545)
- ☐ I-cell disease (546)
- ☐ Wolman disease (547)
- ☐ Glucose storage disease (548)
- ☐ Mucopolysaccharidoses, not otherwise specified (540)

#### Polysaccharide hydrolase abnormalities

- ☐ Aspartyl glucosaminidase (561)
- ☐ Fucosidosis (562)
- ☐ Mannosidosis (563)
- ☐ Polysaccharide hydrolase abnormality, not otherwise specified (560)
- ☐ Other inherited metabolic disorder (529) – **Go to question 634278**
- ☐ Inherited metabolic disorder, not otherwise specified (520)

281. Specify other inherited metabolic disorder: \_\_\_\_\_

- **Go to signature line**

#### Histiocytic disorders

282. Specify histiocytic disorder classification:

- ☐ Hemophagocytic lymphohistiocytosis (HLH) (571)
- ☐ Langerhans cell histiocytosis (histiocytosis-X) (572)
- ☐ Hemophagocytosis (reactive or viral associated) (573)
- ☐ Malignant histiocytosis (574)
- ☐ Other histiocytic disorder (579) – **Go to question 636280**
- ☐ Histiocytic disorder, not otherwise specified (570)

283. Specify other histiocytic disorder: \_\_\_\_\_

- **Go to signature line**

#### Autoimmune Diseases

284. Specify autoimmune disease classification:

**Arthritis**

- ☐ Rheumatoid arthritis (603)
- ☐ Psoriatic arthritis / psoriasis (604)
- ☐ Juvenile idiopathic arthritis (JIA): systemic (Stills disease) (640)
- ☐ Juvenile idiopathic arthritis (JIA): oligoarticular (641)
- ☐ Juvenile idiopathic arthritis (JIA): polyarticular (642)
- ☐ Juvenile idiopathic arthritis (JIA): other (643) **Go to question [638282](#)**
- ☐ Other arthritis (633) – **Go to question [639283](#)**

**Multiple sclerosis**

- ☐ Multiple sclerosis (602)

**Connective tissue diseases**

- ☐ Systemic sclerosis (scleroderma) (607)
- ☐ Systemic lupus erythematosus (SLE) (605)
- ☐ Sjögren syndrome (608)
- ☐ Polymyositis / dermatomyositis (606)
- ☐ Antiphospholipid syndrome (614)
- ☐ Other connective tissue disease (634) – **Go to question [640284](#)**

**Vasculitis**

- ☐ Wegener granulomatosis (610)
- ☐ Classical polyarteritis nodosa (631)
- ☐ Microscopic polyarteritis nodosa (632)
- ☐ Churg-Strauss (635)
- ☐ Giant cell arteritis (636)
- ☐ Takayasu (637)
- ☐ Behcet syndrome (638)
- ☐ Overlap necrotizing arteritis (639)
- ☐ Other vasculitis (611) – **Go to question [641285](#)**

**Other neurological autoimmune diseases**

- ☐ Myasthenia gravis (601)
- ☐ Other autoimmune neurological disorder (644) – **Go to question [642286](#)**

**Hematological autoimmune diseases**

- ☐ Idiopathic thrombocytopenic purpura (ITP) (645)
- ☐ Hemolytic anemia (646)
- ☐ Evan syndrome (647)
- ☐ Other autoimmune cytopenia (648) – **Go to question [643287](#)**

**Bowel diseases**

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

☐ Crohn's disease (649)

☐ Ulcerative colitis (650)

☐ Other autoimmune bowel disorder (651) – **Go to question [644288](#)**

285. Specify other arthritis: \_\_\_\_\_

286. Specify other juvenile idiopathic arthritis (JIA): \_\_\_\_\_

287. Specify other connective tissue disease: \_\_\_\_\_

288. Specify other vasculitis: \_\_\_\_\_

289. Specify other autoimmune neurological disorder: \_\_\_\_\_

290. Specify other autoimmune cytopenia: \_\_\_\_\_

291. Specify other autoimmune bowel disorder: \_\_\_\_\_

**- Go to signature line**

#### Other Disease

292. Specify other disease: \_\_\_\_\_

First Name: \_\_\_\_\_

Last Name: \_\_\_\_\_

E-mail address: \_\_\_\_\_

Date: \_\_\_\_\_  
                    YYYY                    MM                    DD